OBJECTIVES: Although the existence of metabolically healthy obese (MHO) individuals has been recognized, little is known regarding metabolic health status in these subjects over time. Thus, we evaluated longitudinal changes in metabolic parameters among MHO subjects compared with metabolically healthy, normal-weight (MHNW) subjects. METHODS: A cohort study was performed on 2599 Korean men, 30 --59 years of age, with no evidence of fatty liver disease on ultrasound and no traits of metabolic syndrome at baseline. BMI was categorized based on criteria for Asian population. Study participants were followed annually or biennially between 2002 and 2009. At each visit, the fatty liver on ultrasound was assessed and metabolic abnormalities were measured. Parametric Cox models and a pooled logistic regression models were used to evaluate the relationships of BMI with incident metabolic abnormalities. RESULTS: During 9647.1 person-years of follow-up, 1673 participants developed metabolic abnormalities. After adjusting for age, smoking, alcohol intake and exercise, higher baseline BMI categories predicted increased incidences of metabolic abnormalities in a dose-response manner. The hazard ratios (95% confidence intervals) for hypertriglyceridemia, prediabetes, pre-hypertension, low high-density lipoprotein-cholesterol, fatty liver, elevated high sensitivity-C reactive protein, elevated homeostasis model assessment of insulin resistance, any metabolic abnormality and metabolic syndrome among the MHO subjects compared with the MHNW subjects were 1.51 (1. Keywords: body mass index; risk factors; insulin resistance; metabolic syndrome X; follow-up studies
INTRODUCTION
Obesity is a risk factor for cardiometabolic disorders such as type 2 diabetes mellitus and cardiovascular disease.
1,2 However, the incidence of obesity-related metabolic disturbances varies widely among obese individuals. 3, 4 A unique subset of obese individuals that appears to be protected from obesity-related metabolic abnormalities has been identified. 3, 5 These individuals, referred to as metabolically healthy but obese (MHO), are relatively insulin sensitive and have a favorable cardiovascular risk profile despite excessive body fat. 6 Previous studies indicate that MHO individuals, regardless of body mass index, are not at increased risk for cardiovascular diseases compared with normal-weight subjects without insulin resistance. 7, 8 Therefore, weight loss may not be deemed necessary among these individuals.
Recent longitudinal studies have observed that obese men without metabolic syndrome were at an increased risk for cardiovascular events or death compared with normal-weight individuals without metabolic syndrome. 9, 10 Other studies observed that the MHO subset had an intermediate cardiovascular risk between healthy non-obese subjects and insulin resistant subjects. 11, 12 Furthermore, recent intervention studies showed that lifestyle-induced weight loss among MHO individuals was associated with improved insulin sensitivity. 13, 14 Although the existence of MHO individuals has been recognized, little is known regarding the metabolic changes in MHO individuals over time compared with metabolically healthy, normal-weight (MHNW) individuals. Therefore, the purpose of this study was to assess longitudinal changes over time in selected metabolic parameters among MHO subjects compared with MHNW subjects.
SUBJECTS AND METHODS Subjects
The study sample included male employees of one of the largest semiconductor manufacturing companies in Korea and its 13 affiliates. 15 --17 In Korea, the Industrial Safety and Health Law requires that employees participate in annual or biennial health examinations. The potential subjects were all male and ranged from 30 to 59 years of age. All participated in comprehensive health examinations at the Kangbuk Samsung Hospital, Seoul, Korea in 2002 (N ¼ 15 347) including ultrasound examinations of the liver.
For this analysis, we excluded participants with any metabolic syndrome components, with evidence of liver disease, or with factors that could influence metabolic syndrome traits or ultrasonographic findings of the liver. Applying these criteria, we excluded 27 subjects with histories of malignancy; 16 subjects with histories of cardiovascular disease; 125 subjects with current use of antihyperlipidemics; 3031 subjects with fasting blood glucose X5.55 mmol l À1 or currently using blood glucose-lowering agents; 3823 subjects with blood pressure X130/85 mm Hg or currently using blood pressure-lowering agents; 6277 subjects with elevated triglyceride levels X1.69 mmol l À1 ; 1894 subjects with low high-density lipoprotein-cholesterol (HDL-C) o1.03 mmol l À1 ; 5053 subjects with ultrasonographic evidence of fatty liver; 2498 subjects reporting alcohol intakes of at least 20 g per day; 18 2181 subjects with homeostasis model assessment of insulin resistance (HOMA-IR) X2.5;
10,19 4132 subjects with high sensitivity-C reactive protein (hsCRP) X1.0 mg l; 4 11 subjects currently taking medications for hepatitis; 841 subjects with positive serologic markers for hepatitis B or C virus and reported histories of known liver disease (including viral, genetic, autoimmune and drug-induced liver disease), or with abnormal liver ultrasonographic findings (indicating chronic liver disease, liver cirrhosis, intrahepatic or extrahepatic cholelithiasis, or abnormal dilatation of the biliary tree); and 431 subjects who had taken medications within the past year that could affect the development of hepatic steatosis (such as steroids, immune suppressants, anticonvulsants and tetracycline). We further excluded 824 subjects with missing baseline data. Because some individuals met more than one criterion for exclusion, the total number of eligible subjects for the study was 2857 at baseline. After starting the study, a further 258 subjects (9.0%) were excluded for not attending any follow-up visits between 2002 and 2009. Of the 2857 eligible participants at baseline, no variables differed between participants lost to follow-up and those with successful follow-up (data not shown). Ultimately, 2599 subjects were enrolled in the analysis. This study was approved by the Institutional Review Board of Kangbuk Samsung Hospital, which exempted the requirement for informed consent as we only retrospectively accessed data that were de-identified.
Measurements
Baseline and follow-up examinations were conducted at the Kangbuk Samsung Hospital Health Screening Center. Study subjects were examined annually or biennially between Jaunary 2002 and December 2009. Data on medical history, medication use, health-related behaviors, physical measurements and serum biochemical measurements were collected during health examinations. 16 Questions regarding alcohol intake included weekly frequency of alcohol consumption and usual daily amount of consumption. Questionnaire data were also used to identify current smokers and to assess the weekly frequency of moderate-or vigorousintensity physical activity. Body weight was measured in light clothing and no shoes to the nearest 0.1 kg using a digital scale. Height was measured to the nearest 0.1 cm. Body mass index was calculated as weight in kilograms divided by height in meters squared. Trained nurses measured sitting blood pressure with standard mercury sphygmomanometers. These variables were assessed at each visit. 15 Blood samples were taken from the antecubital vein after 412 h of fasting. Serum levels of glucose, uric acid, total cholesterol, triglyceride, low-density lipoprotein cholesterol, HDL-C, gamma-glutamyltransferase, alanin aminotransferase and aspartate aminotransferase were measured using Bayer Reagent Packs on an automated chemistry analyzer (Advia 1650 Autoanalyzer; Bayer Diagnostics, Leverkusen, Germany).
Measurement techniques included the hexokinase method for glucose, an enzymatic colorimetric assay for serum lipids and an immunoradiometric assay for insulin (Biosource, Nivelles, Belgium). Serum uric acid was measured based on the Fossati enzymatic reaction using an uricase with a Trinder-like endpoint (ADVIA 1650 Auto Analyzer; Bayer Diagnostics). Insulin resistance was assessed with HOMA-IR, according to the following equation: fasting blood insulin (mU ml À1 ) Â fasting blood glucose (mmol l À1 ) /22.5. hsCRP was analyzed by particle-enhanced immunonephelometry with the BNII System (Dade Behring, Marburg, Germany) using a lower detection limit of 0.175 mg l
À1
. The clinical laboratory was accredited and participates annually in inspections and surveys by the Korean Association of Quality Assurance for Clinical Laboratories.
Abdominal ultrasounds were performed using a 3.5-MHz transducer (Logic Q700 MR; GE, Milwaukee, WI, USA) by 12 experienced radiologists, who were unaware of the aims of the study and blinded to laboratory values. Images were captured in a standard fashion with the patient in the supine position and the right arm raised above the head 16 . An ultrasonographic diagnosis of fatty liver was defined as the presence of a diffuse increase of fine echoes in the liver parenchyma compared with the kidney or spleen parenchyma. 20 Ultrasonographic diagnoses of fatty liver were determined by radiologists using liver images.
Metabolic syndrome was defined using the modified National Cholesterol Education Program Adult Treatment III 21 as the presence of three or more among the following criteria: (1) abdominal obesity; (2) fasting blood glucose X5.55 mmol l À1 ; 22 (3) triglycerides X1.69 mmol l À1 ; (4) HDL-C o1.03 mmol l À1 and (5) blood pressure X130/85 mm Hg. Triglycerides, HDL-C, glucose and blood pressure were determined at each visit. As waist circumference was not available, four (of usual five) components for metabolic syndrome were calculated at each visit. Triglycerides, HDL-C, glucose and blood pressure were measured at each visit. Additionally, hsCRP, HOMA-IR and fatty liver, which is considered another feature of metabolic sydnrome, 23, 24 were also determined at each visit. When measuring insulin resistance, we used a stringent definition with a HOMA-IR cutoff of 2.5, which is associated with clamp-measured IR. 19 As there is no standard definition for MHO, we considered seven metabolic abnormalities for our analyses: (1) Weight changes were calculated for each subject as 'visit 2 weight' minus 'baseline (visit 1) weight'. The distribution of continuous variables was evaluated and appropriate transformations were performed during analysis, as needed.
Incidence density was expressed as the number of cases divided by person-years. The cumulative incidence of 1, 2 and 5 years was expressed by a simple proportion. Incidences of various metabolic abnormalities stratified by BMI group were also assessed by Kaplan --Meier plots. Followup extended from the baseline exam until the development of each metabolic abnormality or the last health exam conducted for each participant. As we knew that metabolic abnormalities had occurred between two visits but did not know the precise time of each metabolic abnormality development, we used a parametric Cox model to take into account this type of interval censoring (stpm command in Stata). 27 In these models, the baseline hazard function was parameterized with restricted cubic splines in log time with four degrees of freedom. We estimated adjusted hazard ratios (and 95% confidence intervals (CI)) for incident each metabolic abnormality comparing the metabolically healthy underweight, metabolically healthy overweight and MHO to the MHNW. For timedependent analyses, we used a pooled logistic regression model that closely approximates a Cox model when the risk of outcome between intervals is low. 28 The models were initially adjusted for age, then for body mass index, smoking, alcohol intake and exercise. To determine linear trends of risk, the number of categories or quartiles was used as a continuous variable and tested on each model. We assessed the proportional hazards assumption by examining graphs of estimated log(-log) survival.
The statistical analysis of the data was carried out using STATA version 11.0 (StataCorp LP, College Station, TX, USA). All reported P-values are two tailed and those o0.05 were considered statistically significant.
RESULTS
At baseline, the mean age and BMI of the 2599 participants were 36.1 years (s.d., 4.6) and 22.3 kg m À2 (s.d., 2.3, range 15.1 --31.8), respectively. The average follow-up period for subjects who did not develop any metabolic abnormalities was 5.1 years. There was similarity in the average follow-up time across BMI categories.
The baseline characteristics of the study participants in relation to BMI categories are outlined in Table 1 . There were clear doseresponse relationships between all of the listed variables and BMI categories. Age, fasting blood glucose, systolic and diastolic blood pressures, total cholesterol, triglycerides, low-density lipoprotein cholesterol, uric acid, insulin, HOMA-IR, hsCRP, exercise and current alcohol use were positively associated with BMI; whereas HDL-C and current smoking were inversely associated with BMI.
During 9647.1 person-years of follow-up, 1673 participants developed metabolic abnormalities. Cumulative incidences of any metabolic abnormality were 4.9, 23.6 and 53.6% at 1, 2 and 5 year, respectively ( Figure 1 ). The incidence densities of metabolic syndrome itself, and hypertriglyceridemia, prediabetes, prehypertension and low HDL-C among each metabolic syndrome trait were 0.6 per 100 person-years (95% CI, 0.5 --0.8), 6.3 per 100 person-years (95% CI, 5.9 --6.8), 8.1 per 100 person-years (95% CI, 7.6 --8.7), 5.3 per 100 person-years (95% CI, 4.9 --5.7) and 2.0 per 100 person-years (95% CI, 1.8 --2.2), respectively. The incidence densities of USFL, elevated hsCRP and elevated HOMA-IR were 5.0 per 100 person-years (95% CI, 4.6 --5.4), 8.2 per 100 person-years (95% CI, 7.7 --8.7) and 4.2 per 100 person-years (95% CI, 3.9 --4.6), respectively. Table 2 shows the risk of developing each metabolic abnormality according to baseline BMI category. We first analyzed the relationships between baseline BMI and each outcome adjusting for age only; then, we adjusted for age, smoking, drinking and regular exercise. In both models, higher baseline BMI categories predicted the incidences of all metabolic abnormalities in a dose-response manner (P for trend o0.05). The risk for developing any one metabolic abnormality also increased across the BMI categories (P for trend o0.001). Compared with the MHNW group, the MHO group was at a significantly elevated risk for hypertriglyceridemia (aHR, 1.51; 95% CI, 1. In time-dependent models, the risk for hypertriglyceridemia, pre-hypertension, low HDL-C, USFL, elevated HOMA-IR and any metabolic abnormality increased across BMI categories. Additionally, the risk for prediabetes and elevated hsCRP did not increase significantly across the BMI categories in time-dependent models.
When analyses were restricted to participants with stable weight change ( --1.0 to 1.0 kg) over 1.8 years (n ¼ 820) from visit 1 to visit 2, the risk of developing any one of the metabolic abnormalities increased across the BMI categories (P for trend o0.001) ( Table 3 ). The MHO group was also at a significantly elevated risk for all metabolic abnormalities except elevated hsCRP and metabolic syndrome itself compared with the MHNW group.
We also examined the association between the development of each metabolic abnormality and metabolic syndrome itself, and weight change (kg) over 1.8 years, between visit 1 and visit 2, among men who had two or more weight measurements before each metabolic abnormality assessment (n ¼ 1143) (Supplementary Table 1 ). The risk for all metabolic abnormality except hypertriglyceridemia did not increase significantly with increasing quartiles of weight change. In both age-adjusted and multivariate-adjusted analyses, however, the risk for hypertriglyceridemia increased with increasing quartiles of weight change (P for trend o0.05). Subjects in the fourth quartile (weight gain X2.3 kg) were at a significantly elevated risk for hypertriglyceridemia (aHR, 1.60; 95% CI, 1.10 --2.34).
We further examined the difference between persistent MHO individuals (n ¼ 257) who maintained metabolically healthy and failed MHO individuals (n ¼ 72) who developed one or more of metabolic abnormalities (Supplementary Table 2 ). Persistent MHO individuals showed better profile at baseline, compared with failed MHO individuals who were older and had higher triglycerides and blood glucose level at baseline.
DISCUSSION
To our knowledge, this is the first study regarding whether or not MHO individuals maintain metabolic health over time. We investigated changes that might take place in MHO subjects' metabolic profiles over time.
Compared with MHNW individuals, MHO individuals had increased incidences of metabolic abnormalities. Although metabolically healthy subjects were exclusively selected for participation in this study, we found that higher baseline BMI categories predicted increased incidences of all metabolic abnormalities (hypertriglyceridemia, prediabetes, pre-hypertension, low HDL-C, USFL, elevated hsCRP and elevated HOMA-IR) and metabolic syndrome in a dose-response manner.
Even after adjustment for updated weight over time, we still found a strong association between higher BMI and increase incidence of metabolic abnormalities, which are risk factors for cardiovascular disease. Additionally, in further separate restricted analysis of subjects with stable weight change (--1.0 to 1.0 kg) over 1.8 years from visit 1 to visit 2 we still observed the same association.
Recent longitudinal studies have observed that obese men without metabolic syndrome had an increased risk of diabetes, 29 cardiovascular events and death 9,10 compared with MHNW individuals. Individual metabolic components, defined as an endpoint in our study, are important predictors for diabetes and future cardiovascular events. 30 --33 Previous studies have shown that having even one metabolic component is a risk factor for cardiovascular mortality, 34, 35 with each additional component increasing this risk incrementally. 35 In the present study, obesity was positively correlated with a higher incidence of metabolic abnormalities in MHO individuals over time compared with MHNW subjects. This suggests that over time, many of MHO individuals undergo adverse metabolic changes associated with obesity. Our findings may explain why MHO individuals had a higher risk for incident diabetes 29 and cardiovascular events, 9,10 compared with MHNW individuals. Additionally, even though metabolically healthy subjects were exclusively selected for this study, baseline values of metabolic parameters increased across the BMI categories. Liver enzyme levels also increased across the BMI categories. These findings are consistent with a previous cross-sectional study concluding that MHO subjects have less favorable profiles than metabolically healthy non-obese subjects. 11 However, about 20% of MHO individuals still maintained metabolically healthy during the follow-up period, and they are likely to be younger and have better profile of glucose and triglycerides than failed MHO individuals who developed any Estimated from Parametric Cox models adjusted for age, smoking status, alcohol intake, and regular exercise at baseline.
b Estimated from a pooled logistic regression models with BMI as a time-dependent variable adjusted for other covariates (baseline age and current smoker, current alcohol use, and regular exercise over time as time-dependent variables). Hypertriglyceridemia was defined as a fasting triglycerides level X1.69 mmol l
À1
. Pre-diabetes was defined as a fasting serum glucose X5.55 mmol l À1 or current use of blood glucose lowering agents. Pre-hypertension was defined as a blood pressure X130/85 mm Hg or current use of blood pressure lowering agents. Impact of BMI on the incidence of metabolic abnormalities Y Chang et al Table 3 . Association between baseline body mass index and the development of each metabolic abnormality and metabolic syndrome itself among men with stable weight change ( --1.0 --1.0 kg) over 1.8 years from visit 1 to visit 2 (n ¼ 820) Estimated from Parametric Cox models adjusted for age, smoking status, alcohol intake, and regular exercise at baseline.
. Pre-diabetes was defined as a fasting serum glucose X5.55 mmol l À1 or current use of blood glucose lowering agents. Pre-hypertension was defined as a blood pressure X130/85 mm Hg or current use of blood pressure lowering agents. metabolic abnormalities. Previous studies showed that duration of obesity is an independent risk factor for adverse health outcome. 36, 37 Therefore, establishing MHO individuals will require additional studies that observe longer enough and further assess obesity duration and weight history in depth.
There are several limitations to this study. First, the definition of IR used in this study was based on insulin levels and HOMA analyses and not on euglycemic insulin clamp analyses, which are invasive and time consuming. However, HOMA-IR and the euglycemic hyperinsulinemic glucose clamp procedure have shown strong correlations in other studies (0.6 --0.88). 38 A second limitation of our study is the use of BMI as a measure of obesity because it cannot distinguish between fat tissue and lean tissue. However, if the MHO group in this study might have higher lean tissue than fat mass, the association between higher BMI categories and the development of metabolic abnormalities could be attenuated. Additionally, we applied stingent definition for metabolic abnormality (for example, insulin resistance as HOMA-IR X2.5;
10,19 elevated hsCRP as hsCRP X1.0 mg l À1; (ref. 4) and fatty liver as another feature of metabolic abnormatliy 23, 24 ) and applied it when we selected study population. Likewise, even in exclusively metabolically healthy subjects, this study found that MHO individuals had less favorable changes in metabolic parameters over time than MHNW individuals. Lastly, our findings cannot be simply extrapolated to women and other populations.
Despite these limitations, this study shows that obesity is positively correlated with an increased incidence of individual metabolic syndrome traits over time, even in metabolically healthy Korean men. Our study suggests that individuals considered to be MHO are not as healthy as MHNW individuals. Therefore, physicians should carefully monitor their overweight and obese patients, keeping a cautious watch over their metabolic profiles in addition to counseling them about healthy weight and lifestyle.
